Answer Happy

December 1, 2020 Researchers at Oxford University published a study in The Lancet about human trials of a potential coronavirus vaccine they developed and began testing in April 2020. The research was funded by a £20 million ($24 million) grant from the U.K's National Health Service. The vaccine was made from a weakened version of a common cold virus that causes infections in chimpanzees. It was modified to make it impossible to grow in humans. Proteins from the Covid-19 virus's outer coat were then added. "We hoped the body would recognize and develop an immune response to the COVID-19 protein that will help stop the SARS-CoV-2 virus from entering human cells and therefore prevent infection," the University said. In the trial 1,068 volunteers were recruited. They were assigned by a flip of a coin to either be injected with the coronavirus vaccine or to receive a control - a widely available meningitis vaccine. Volunteers, who lived in a variety of locations around the U.K., were then followed for 6 months. The researchers performed laboratory tests each week to determine if the volunteers had contracted COVID-19 (the disease caused by the coronavirus). The following are the results of the study: Number of people Number of cases of COVID-19 Number of COVID-19 deaths 527 53 (10.0%) 15 (2.8%) People who received the coronavirus vaccine People who received the meningitis vaccine 541 97 (17.9%) 31 (5.7%) "Mortality rate is based on the number of people in the study group. Mortality rate can be calculated Watanalarimbarcaces

"Mortality rate is based on the number of people in the study group. Mortality rate can be calculated based on population total or number of cases. Question: What is the best hypothesis for this study? O Vaccines should be tested in chimpanzees. Oxford University will cure COVID-19. Oxford University's coronavirus vaccine will decrease infection from the coronavirus. Meningitis vaccines will decrease infection from the coronavirus.